Explore

Rapid Read Rapid Read
UNC5B Signaling Identified as Key Driver in Pancreatic Cancer Metastasis

UNC5B Signaling Identified as Key Driver in Pancreatic Cancer Metastasis

Recent research has identified the UNC5B receptor as a significant factor in the progression of pancreatic ductal adenocarcinoma (PDAC), a type of pancreatic cancer. The study, conducted using genetically engineered mouse models, demonstrated that UNC5B is highly expressed in PDAC and plays a crucial role in the epithelial-to-mesenchymal transition (EMT), a process that facilitates cancer metastasis. The research highlights the potential of NP137, an antibody drug that inhibits the Netrin-1/UNC5B interaction, as a therapeutic option to prevent EMT and metastasis in PDAC. This discovery opens up new avenues for clinical trials aimed at testing the efficacy of NP137 in human pancreatic cancer patients.
Rapid Read Rapid Read
Study Links Fructose to Metastasis in Aggressive Ovarian Cancer

Study Links Fructose to Metastasis in Aggressive Ovarian Cancer

A study published in Nature Aging reveals that fructose may play a role in promoting metastasis in high-grade serous ovarian cancer (HGSOC), the most common type of ovarian cancer. Researchers found that cancer cells surviving chemotherapy use fructose as a signaling molecule, potentially driving cancer recurrence. The study highlights that fructose, abundant in the signaling molecules released by senescent cancer cells, can cause cancer cells to detach and metastasize. The findings suggest a possible link between high fructose consumption and cancer progression, raising questions about dietary interventions to reduce metastasis risk.
Trendline Trendline
Bicycle Therapeutics Reports Progress and Financial Results for Q2 2026

Bicycle Therapeutics Reports Progress and Financial Results for Q2 2026

Bicycle Therapeutics Reports Progress and Financial Results for Q2 2026
Trendline Trendline
Moderna Reports Q2 2026 Earnings: Revenue Growth and Pipeline Expansion Amid Challenges

Moderna Reports Q2 2026 Earnings: Revenue Growth and Pipeline Expansion Amid Challenges

Moderna Reports Q2 2026 Earnings: Revenue Growth and Pipeline Expansion Amid Challenges
Rapid Read Rapid Read
Israeli Study Finds Uneven Aging in Cells, Potential for Targeted Cancer Treatments

Israeli Study Finds Uneven Aging in Cells, Potential for Targeted Cancer Treatments

Researchers at the Hebrew University of Jerusalem have discovered that aging occurs unevenly across different cells in the body, challenging the traditional view of uniform aging. Led by Prof. Howard Cedar, the study identifies a molecular 'aging signature' that reveals which cells age faster. This finding, published in Nature Communications, suggests that targeting these rapidly aging cells could lead to new treatments for age-related diseases, including cancer. The research highlights the role of DNA methylation in regulating gene activity and its impact on cellular aging.
Trendline Trendline
Orano Med Reports Progress in Cancer Treatment Development and Business Expansion

Orano Med Reports Progress in Cancer Treatment Development and Business Expansion

Orano Med Reports Progress in Cancer Treatment Development and Business Expansion
Rapid Read Rapid Read
CRISPR Technology Advances Prostate Cancer Research with SKP2 Humanized Mice

CRISPR Technology Advances Prostate Cancer Research with SKP2 Humanized Mice

Researchers at the University of California Irvine have developed a prostate-specific SKP2 humanized mouse model using CRISPR technology. This model allows for the study of neoplastic initiation and microenvironmental reprogramming in prostate cancer. By knocking in the human SKP2 gene into mice, scientists can observe the role of SKP2 in cancer progression and its interaction with the tumor microenvironment. This research provides a new platform for understanding the molecular mechanisms of prostate cancer and testing potential therapeutic interventions.
Rapid Read Rapid Read
New Biomarker Framework Proposed for Hepatocellular Carcinoma Immunotherapy

New Biomarker Framework Proposed for Hepatocellular Carcinoma Immunotherapy

Recent research has synthesized evidence from 2023 to 2026 to propose a new clinical integration framework for using tissue and blood-based predictive biomarkers in hepatocellular carcinoma (HCC) immunotherapy. Despite the establishment of immunotherapy as a first-line treatment, objective response rates remain low, and no validated predictive biomarkers exist for patient selection. The study evaluates various biomarkers, including AI-derived models and circulating tumor DNA, to improve patient outcomes. The research suggests a biomarker-guided clinical algorithm to enhance treatment efficacy and proposes prospective trials for further validation.
Rapid Read Rapid Read
Pancreatic Cancer Drug Daraxonrasib Extends Survival in Phase 3 Trial

Pancreatic Cancer Drug Daraxonrasib Extends Survival in Phase 3 Trial

A phase 3 trial has shown that the drug daraxonrasib nearly doubles the median overall survival for patients with previously treated metastatic pancreatic cancer. The trial involved 500 patients and extended survival to 13.2 months compared to 6.7 months with standard chemotherapy. Despite not being a cure, the drug represents a significant advancement in treating a cancer with a high mortality rate. Daraxonrasib targets the KRAS gene, which is mutated in over 90% of pancreatic tumors. The drug is not yet approved, but an expanded access protocol allows certain patients to receive it outside of clinical trials.
Rapid Read Rapid Read
Israel Initiates Groundbreaking Trial for Pancreatic Cancer Treatment

Israel Initiates Groundbreaking Trial for Pancreatic Cancer Treatment

Tel Aviv Sourasky Medical Center, in collaboration with Silexion Therapeutics, has launched a world-first clinical trial for an experimental treatment targeting KRAS mutations in pancreatic cancer. The trial will evaluate SIL204, a treatment using small interfering RNA molecules to suppress mutated KRAS genes. KRAS mutations are present in approximately 90% of pancreatic cancer cases and are a major driver of tumor growth. The trial aims to assess whether silencing these mutations can inhibit tumor growth in patients with locally advanced pancreatic cancer. The initial phase will enroll 18 patients, focusing on safety, with plans to expand to additional centers in Europe.
Rapid Read Rapid Read
Technion Researchers Secure Grants for Cancer and Heart Disease Studies

Technion Researchers Secure Grants for Cancer and Heart Disease Studies

Three faculty members from the Technion-Israel Institute of Technology have been awarded research grants by the Israel Cancer Research Fund. These grants aim to support innovative research into cancer and its interaction with other health conditions. Professor Irit Ben Aharon is investigating the effects of chemotherapy on children born to mothers who underwent cancer treatment during pregnancy. Dr. Ido Livneh is exploring the 'backup systems' that allow cancer cells to survive treatment. Dr. Shira Landau is developing an Organ-on-a-Chip model to study the interaction between cancer and heart disease. These studies are part of a broader effort to understand and manage cancer as a chronic disease.
Rapid Read Rapid Read
Research Identifies Prognostic Genes in Breast Cancer for Improved Treatment Options

Research Identifies Prognostic Genes in Breast Cancer for Improved Treatment Options

A recent study published in Frontiers in Genetics has identified key prognostic genes related to neutrophil extracellular traps (NETs) and inflammation in breast cancer. The research, conducted by a team from Nanchang People's Hospital in China, focused on understanding the interaction between NET-driven necrosis-related genes (NRGs) and inflammation-related genes (IRGs) in breast cancer. The study identified several prognostic genes, including ZMYND10, IL12B, CXCL13, TFF1, LTB, and SPIB, which are associated with differential immune cells. The research also developed a risk model and nomogram for breast cancer prognosis using bioinformatics methods, which could aid in improving clinical outcomes and treatment strategies.